BIO announced survey tool on FDA/Sponsor Interactions During Drug Development to better inform policy initiatives designed to improve FDA and drug sponsor coordination and communication during drug development. Survey will serve to inform next reauthorization of the Prescription Drug User Fee Act VI. By helping to identify areas where policies, regulations, and practices are working well and areas that need improvement, sponsor input will make process more efficient and effective.
This story is related to the following:Trade Associations